OncoMed Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 37,779 24,681 31,409
Cost of Revenue - - -
Gross Profit 37,779 24,681 31,409
Operating Expenses
Research and Development 50,048 39,893 40,058
Sales, General and Admin. 11,630 7,157 6,591
Non-Recurring Items - - -
Other - - -
Operating Income (23,899) (22,369) (15,240)
Income From Continuing Operations
Add'l Income/Expense Items (228) 140 244
Earnings Before Interest and Tax (24,127) (22,229) (14,996)
Interest Expense - 6 38
Earnings Before Tax (24,127) (22,235) (15,034)
Income Tax 1,944 - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (26,071) (22,235) (15,034)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (26,071) (22,235) (15,034)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (26,071) (22,235) (15,034)